Italy Regenerative Medicine Market Size & Outlook, 2025-2030
Italy Regenerative Medicine Market, 2018-2030 (US$M)
Global Market
Related Markets
Italy regenerative medicine market highlights
- The Italy regenerative medicine market generated a revenue of USD 1,176.7 million in 2024 and is expected to reach USD 3,186.0 million by 2030.
- The Italy market is expected to grow at a CAGR of 18.1% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Banks is the most lucrative product segment registering the fastest growth during the forecast period.
Regenerative medicine market data book summary
| Market revenue in 2024 | USD 1,176.7 million |
| Market revenue in 2030 | USD 3,186.0 million |
| Growth rate | 18.1% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Banks |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Tools, Banks, Services |
| Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, Italy accounted for 3.3% of the global regenerative medicine market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK regenerative medicine market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 505.3 million by 2030.
Italy makes a significant contribution to the regenerative medicine market with the development of gene therapy products approved in Europe. The active engagement of the country in this space is considered a key factor for market growth. Moreover, companies operating in the country are forming partnerships for gene and cell therapy manufacturing. For instance, in July 2020, MolMed S.p.A extended its collaboration with a UK-based company, Orchard Therapeutics, for gene and cell therapy manufacturing.
MolMed S.p.A. is the first company with GMP authorization for gene and cell therapy manufacturing in Europe. The increasing approvals & advances in cell therapy, tissue-engineered products, and gene therapy are anticipated to boost the market for regenerative medicine in Italy. The Italian Medicines Agency suggested three gene therapies, Yescarta, Luxturna, and Kymriah, with managed entry agreements in Italy.
No credit card required*
Publish Date: May 30, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Regenerative Medicine Market Scope
Regenerative Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Integra Lifesciences Holdings Corp | View profile | 3,946 | 1100 Campus Road, Princeton, NJ, United States, 08540 | www.integralife.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Vericel Corp | View profile | 314 | 64 Sidney Street, Cambridge, MA, United States, 02139 | www.vcel.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
Italy Regenerative Medicine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Regenerative Medicine Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 90.71% in 2024.
Horizon Databook has segmented the Italy regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
Italy makes a significant contribution to the regenerative medicine market with the development of gene therapy products approved in Europe. The active engagement of the country in this space is considered a key factor for market growth. Moreover, companies operating in the country are forming partnerships for gene and cell therapy manufacturing. For instance, in July 2020, MolMed S.p.A extended its collaboration with a UK-based company, Orchard Therapeutics, for gene and cell therapy manufacturing.
MolMed S.p.A. is the first company with GMP authorization for gene and cell therapy manufacturing in Europe. The increasing approvals & advances in cell therapy, tissue-engineered products, and gene therapy are anticipated to boost the market for regenerative medicine in Italy. The Italian Medicines Agency suggested three gene therapies, Yescarta, Luxturna, and Kymriah, with managed entry agreements in Italy.
- Italy Regenerative Medicine Market Product Outlook (Revenue, USD Million , 2018-2030)
- Therapeutics
- Tools
- Banks
- Services
- Italy Regenerative Medicine Market Therapeutic Outlook (Revenue, USD Million , 2018-2030)
- Dermatology
- Musculoskeletal
- Immunology & Inflammation
- Oncology
- Cardiovascular
- Ophthalmology
- Others
Reasons to subscribe to Regenerative Medicine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Regenerative Medicine Market Outlook databook
- Our clientele includes a mix of Regenerative Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Regenerative Medicine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Regenerative Medicine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Italy Regenerative Medicine Market, 2018-2030 (US$M)
Italy regenerative medicine market statistics, by product, 2018-2030 (US$M)
